These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 33094635)

  • 1. Impact of Obesity on Warfarin Reversal With Fixed-Dose Factor VIII Inhibitor Bypassing Activity (aPCC).
    McKinney AL; Dailey LM; McMillen JC; Rowe AS
    Ann Pharmacother; 2021 Jul; 55(7):856-862. PubMed ID: 33094635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated Prothrombin Complex Concentrate versus Plasma for Reversal of Warfarin-Associated Hemorrhage.
    Rowe AS; Mahbubani PS; Bucklin MH; Clark CT; Hamilton LA
    Pharmacotherapy; 2016 Nov; 36(11):1132-1137. PubMed ID: 27726162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversal of Warfarin-Associated Major Hemorrhage: Activated Prothrombin Complex Concentrate versus 4-Factor Prothrombin Complex Concentrate.
    Peksa GD; Mokszycki RK; Rech MA; Maynard B; Panos NG; Sweis RT; DeMott JM
    Thromb Haemost; 2020 Feb; 120(2):207-215. PubMed ID: 31837652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of 3 Different Prothrombin Complex Concentrate Regimens for Emergent Warfarin Reversal: PCCWaR Study.
    Dietrich SK; Rowe S; Cocchio CA; Harmon AJ; Nerenberg SF; Blankenship PS
    Ann Pharmacother; 2021 Aug; 55(8):980-987. PubMed ID: 33305592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated prothrombin complex concentrate for warfarin reversal in traumatic intracranial hemorrhage.
    Carothers C; Giancarelli A; Ibrahim J; Hobbs B
    J Surg Res; 2018 Mar; 223():183-187. PubMed ID: 29433872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Warfarin Reversal with 4-Factor Prothrombin Complex Concentrate Compared to 3-Factor Prothrombin Complex Concentrate at a Tertiary Academic Medical Center.
    Al-Majzoub O; Rybak E; Reardon DP; Krause P; Connors JM
    J Emerg Med; 2016 Jan; 50(1):7-13. PubMed ID: 26433428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergent Warfarin Reversal With Fixed-Dose 4-Factor Prothrombin Complex Concentrate.
    Jansma B; Montgomery J; Dietrich S; Mixon MA; Peksa GD; Faine B
    Ann Pharmacother; 2020 Nov; 54(11):1090-1095. PubMed ID: 32418445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Effectiveness of Factor VIII Inhibitor Bypassing Activity (FEIBA) and Fresh Frozen Plasma in Oral Anticoagulant-Associated Intracranial Hemorrhage: A Retrospective Analysis.
    Yin EB; Tan B; Nguyen T; Salazar M; Putney K; Gupta P; Suarez JI; Bershad EM
    Neurocrit Care; 2017 Aug; 27(1):51-59. PubMed ID: 28243997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
    Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
    Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Fixed-Dose Four-Factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal in Patients with Intracranial Hemorrhage.
    Scott R; Kersten B; Basior J; Nadler M
    J Emerg Med; 2018 Jun; 54(6):861-866. PubMed ID: 29510892
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocolized use of Factor Eight Inhibitor Bypassing Activity (FEIBA) for the reversal of warfarin induced coagulopathy.
    Htet NN; Barounis D; Knight C; Umunna BP; Hormese M; Lovell E
    Am J Emerg Med; 2020 Mar; 38(3):539-544. PubMed ID: 31176578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experiences with an activated 4-factor prothrombin complex concentrate (FEIBA) for reversal of warfarin-related bleeding.
    Stewart WS; Pettit H
    Am J Emerg Med; 2013 Aug; 31(8):1251-4. PubMed ID: 23763937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation.
    Endres K; St Bernard R; Chin-Yee I; Hsia C; Lazo-Langner A
    Hematology; 2020 Dec; 25(1):489-493. PubMed ID: 33317427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity increases risk of anticoagulation reversal failure with prothrombin complex concentrate in those with intracranial hemorrhage.
    Chu C; Tokumaru S; Izumi K; Nakagawa K
    Int J Neurosci; 2016; 126(1):62-6. PubMed ID: 25430740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of thrombotic complications related to weight-based dosing of activated prothrombin complex concentrate (aPCC) for reversal of apixaban and rivaroxaban in obese patients.
    Whitaker C; McKinney A; Bollig R; Hieb N; Roberts RF; Rowe AS
    J Thromb Thrombolysis; 2022 May; 53(4):861-867. PubMed ID: 34787787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of fixed dose 4-factor prothrombin complex concentrate for emergent warfarin reversal.
    Klein L; Peters J; Miner J; Gorlin J
    Am J Emerg Med; 2015 Sep; 33(9):1213-8. PubMed ID: 26143315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inactivated Four-Factor Prothrombin Complex Concentrate Dosing Practices for Reversal of Warfarin-Related Intracranial Hemorrhage.
    Rhoney DH; La M; Merz M; Cook A; Owusu KA; Roels C; Blunck J; Shewmaker J; Sangha KS; Farrokh S; Lewin J; Chester KW; Human T; Bledsoe K; Greene K; Levesque M; Rocker JC; Davis G; Neyens R; Lassiter TF; Adriance SM
    Neurocrit Care; 2021 Aug; 35(1):130-138. PubMed ID: 33219462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0.
    Zemrak WR; Smith KE; Rolfe SS; May T; Trowbridge RL; Hayes TL; Grindlinger GA; Seder DB
    Neurocrit Care; 2017 Dec; 27(3):334-340. PubMed ID: 28660341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy.
    Wójcik C; Schymik ML; Cure EG
    Int J Emerg Med; 2009 Nov; 2(4):217-25. PubMed ID: 20436891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variables associated with adequate INR reversal in warfarin treated patients receiving 4-factor prothrombin complex concentrate.
    Kjerengtroen S; Chauv S; Hickman AW; Collingridge DS; Fontaine GV
    J Thromb Thrombolysis; 2022 Aug; 54(2):268-275. PubMed ID: 35378715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.